Alternative splicing redefines landscape of commonly mutated genes in acute myeloid leukemia.
Osvaldo D RiveraMichael J MalloryMathieu Quesnel-VallieresRakesh ChatrikhiDavid C. SchultzMartin P CarrollYoseph BarashSara CherryKristen W LynchPublished in: Proceedings of the National Academy of Sciences of the United States of America (2021)
Most genes associated with acute myeloid leukemia (AML) are mutated in less than 10% of patients, suggesting that alternative mechanisms of gene disruption contribute to this disease. Here, we find a set of splicing events that alter the expression of a subset of AML-associated genes independent of known somatic mutations. In particular, aberrant splicing triples the number of patients with reduced functional EZH2 compared with that predicted by somatic mutation alone. In addition, we unexpectedly find that the nonsense-mediated decay factor DHX34 exhibits widespread alternative splicing in sporadic AML, resulting in a premature stop codon that phenocopies the loss-of-function germline mutations observed in familial AML. Together, these results demonstrate that classical mutation analysis underestimates the burden of functional gene disruption in AML and highlight the importance of assessing the contribution of alternative splicing to gene dysregulation in human disease.
Keyphrases
- acute myeloid leukemia
- genome wide identification
- genome wide
- copy number
- allogeneic hematopoietic stem cell transplantation
- end stage renal disease
- ejection fraction
- genome wide analysis
- endothelial cells
- newly diagnosed
- transcription factor
- chronic kidney disease
- poor prognosis
- peritoneal dialysis
- early onset
- late onset
- prognostic factors
- gene expression
- patient reported
- patient reported outcomes
- acute lymphoblastic leukemia
- binding protein
- wild type
- induced pluripotent stem cells